Patricia Balsas

Patricia Balsas

Auto-generated profile, based on publicly available information

Patricia Balsas

Multiscale in Mechanical and Biological Engineering, Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2017 in Blood
Verified
Journal Article
Open access
PDF file
PBPatricia Balsas
Patricia Balsas
JPJara Palomero
Jara Palomero
ÁEÁlvaro Eguileor
Álvaro Eguileor
MRMarta Leonor Rodríguez
Marta Leonor Rodríguez
MVMaria Carmela Vegliante
Maria Carmela Vegliante
VAVirginia Amador
Virginia Amador
SOX11 overexpression in Mantle Cell Lymphoma (MCL) has been associated with more aggresive behavior and worse outcome. However, SOX11 oncogenic pathways driving MCL tumor progression are poorly known. Here, we demonstrate that SOX11 binds to regulatory regions of two important genes for microenvironment-signals in cancer, (C-X-C motif) chemokine receptor 4 (CXCR4) and PTK2 (encoding for focal adhesion kinase (FAK)). Moreover, SOX11-positive xenograft and human primary MCL tumors overexpress cell migration and stromal stimulation gene signatures compared to their SOX11-negative counterparts. We show that SOX11 directly up-regulates CXCR4 and FAK expression, activating PI3K/AKT and ERK1/2 FAK-downstream pathways in MCL. Concordantly, SOX11-positive MCL cells have higher cell migration, transmigration through endothelial cells, adhesion to stromal cells and cell proliferation; and display an increased resistance to conventional drug therapies, compared to SOX11-negative MCL cells. Specific FAK inhibition blocks downstream PI3K/AKT- and ERK1/2-mediated phosphorylation. Additionally, specific FAK- and PI3K-inhibitors reduce SOX11-enhanced MCL cell migration and stromal-interactions, and revert cell adhesion mediated-drug resistance (CAM-DR), to the same levels as SOX11-negative MCL cells. In intravenous MCL xenograft models, SOX11-positive MCL cells display higher cell migration, invasion and growth compared to SOX11-knockdown cells, and specific FAK- and CXCR4-inhibitors impair SOX11-enhanced MCL engraftment in bone marrow. Overall, our results suggest that SOX11 promotes MCL homing and invasion, and increases CAM-DR through the direct regulation of CXCR4 and FAK expression and FAK/PI3K/AKT pathway activation, contributing to a more aggressive phenotype. Inhibition of this pathway may represent an efficient strategy to overcome stromal-mediated chemo-refractoriness in aggressive MCL. Key points SOX11 regulates MCL homing and invasion via direct regulation of CXCR4 and FAK expression, and PI3K/AKT and ERK1/2 signaling activation. SOX11 expression increases cell adhesion mediated-drug resistance (CAM-DR) contributing to a more aggressive MCL phenotype.

20 February 2026 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
PGPaula Guerrero-López
Paula Guerrero-López
PAPilar Alamán-Díez
Pilar Alamán-Díez
SHSoraya Hernández-Hatibi
Soraya Hernández-Hatibi
PBPatricia Balsas
Patricia Balsas
José Manuel García-AznarJosé Manuel García-Aznar
José Manuel García-Aznar
Drug delivery research strongly depends on experimental models that faithfully mimic the tumor microenvironment (TME) and its barriers to evaluate therapeutic efficacy. Conventional systems provide valuable insights but suffer from some limitations in physiological relevance, reproducibility, scalability or translational predictability. In this context, microfluidic 'tumor-on-chip' platforms have emerged as innovative tools that integrate engineering technology to model biological complexity, offering controlled microenvironments to investigate drug penetration, transport dynamics, and therapeutic response. A distinctive aspect of these microsystems is the possibility of incorporating matrices that mimic the extracellular matrix (ECM) of different tissues. These matrices enhance the ability of the in vitro models to replicate the structural, biochemical, and mechanical features of solid tumors. In this review, we focus on the application of microfluidic matrix-integrated tumor-on-chip platforms for drug delivery evaluation. We first outline key microenvironmental features that regulate therapeutic efficacy and discuss how they can be engineered within microfluidic models. We then examine how transport dynamics and delivery mechanisms are modeled under physiologically relevant conditions and review the use of these platforms to assess a broad range of therapeutic strategies, including nanocarriers, biologics, and gene- and cell-based therapies. Finally, we highlight emerging computational and data-driven approaches, together with current translational and regulatory perspectives, that position matrix-integrated tumor-on-chip technologies as powerful preclinical tools. These models aim to bridge the gap between simplified in vitro assays and more complex in vivo studies, ultimately accelerating the translation of drug delivery systems into clinical practice and paving the way for more personalized therapeutic strategies.

28 January 2026 in Acta Biomaterialia
Verified
Journal Article
Open access
PAPilar Alamán-Díez
Pilar Alamán-Díez
SFSilvia Ferrer-Royo
Silvia Ferrer-Royo
CSCarmen Oñate Salafranca
Carmen Oñate Salafranca
PCPablo Martín Compaired
Pablo Martín Compaired
PBPatricia Balsas
Patricia Balsas
AGAlejandra González-Loyola
Alejandra González-Loyola
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest solid tumors and is characterized by aggressive progression, a dense tumor microenvironment (TME), and resistance to conventional therapies. Among the barriers to effective treatments, the presence of elevated interstitial fluid pressure (IFP) may be important for drug penetration and immune cell infiltration. In this work, we present an innovative 3D microfluidic PDAC-on-a-chip that allows the application of IFP in a cell chamber to simulate the TME and evaluate the therapeutic efficacy of CAR-T cells engineered against the tumor receptor EGFR. Elevated IFP was associated with increased tumor spheroid growth, reduced caspase activation and decreased actin remodeling, indicating enhanced tumor resistance. CAR-T cells effectively targeted and eliminated tumor cells in 2D and 3D coculture models under normal pressure conditions. However, under high IFP, CAR-T-mediated cytotoxicity was impaired, indicating that some of the low efficacy of CAR-T-cell therapy against solid tumors might be derived from IFP. These results highlight the importance of the mechanoenvironment in limiting the efficacy of current immunotherapies. Our model, which incorporates an IFP component, serves as a realistic preclinical platform for testing antitumor therapies in solid tumors. Statement of significance In this work, we present an innovative 3D pancreatic tumor-on-a-chip model that incorporates interstitial fluid pressure (IFP), which is a key mechanical component of solid tumors. Using this platform, we discovered that IFP enhances tumor proliferation whilst diminishing immunotherapy efficacy. This indicates the important role of mechanical pressure in limiting immune cell function in solid tumors. Our model is a valuable preclinical platform for investigating the efficacy of anti-tumour therapies and supports the development of strategies to overcome mechanical resistance and enhance therapy efficacy in solid tumors, such as pancreatic cancer.

2 November 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
PGPedro Enrique Guerrero
Pedro Enrique Guerrero
JZJack Zhang-Zhou
Jack Zhang-Zhou
SHSoraya Hernández-Hatibi
Soraya Hernández-Hatibi
AMAlejandro Martín-Contreras
Alejandro Martín-Contreras
PBPatricia Balsas
Patricia Balsas
JGJosé Manuel García-Aznar
José Manuel García-Aznar
Pancreatic ductal adenocarcinoma (PDA) exhibits extensive hypersialylation, a glycosylation hallmark associated with tumor progression and immune evasion. Here, we employed physiologically relevant 3D microfluidic models, which mimic key aspects of the tumor microenvironment, to evaluate the impact of sialyltransferase inhibition using the sialic acid analog Ac 5 3F ax Neu5Ac in PDA cell models. This glycomimetic compound reduced α2,3-sialylation without compromising cell viability in self-organized PDA spheroids. Desialylation decreased the number and velocity of migrating cells in confined and unconfined microenvironments, and reduced cell adhesion to engineered endothelial vessels, consistent with reduced metastatic ability. Notably, 3D co-culture with CAR-T cells revealed enhanced T cell-mediated cytotoxicity upon sialylation inhibition, leading to reduced spheroid size and viability. Collectively, this work provides new insights into the role of sialylation in modulating tumor morphology, cell viability, migratory behavior, and interactions with immune effector cells, underscoring the value of biomimetic microfluidic models for evaluation of anti-metastatic strategies. Overall, targeting hypersialylation reprograms the malignant phenotype of PDA and may enhance immunotherapeutic efficacy, supporting the development of glycan-targeting strategies in cancer therapy.